Edition:
United Kingdom

Opiant Pharmaceuticals Inc (OPNT.OQ)

OPNT.OQ on NASDAQ Stock Exchange Capital Market

22.63USD
22 Feb 2018
Change (% chg)

$-0.09 (-0.40%)
Prev Close
$22.72
Open
$23.50
Day's High
$23.81
Day's Low
$22.43
Volume
6,920
Avg. Vol
12,700
52-wk High
$51.90
52-wk Low
$17.01

Select another date:

Mon, Feb 12 2018

BRIEF-Opiant Pharma Announces Positive Data From A Phase I Clinical Study Of OPNT003

* OPIANT PHARMACEUTICALS INC - ANNOUNCES POSITIVE DATA FROM A PHASE I CLINICAL STUDY OF ITS PRODUCT CANDIDATE OPNT003

BRIEF-Opiant Pharmaceuticals To Record About $11.7 Million In Royalty

* OPIANT PHARMACEUTICALS TO RECORD APPROXIMATELY $11.7 MILLION IN ROYALTY AND MILESTONE PAYMENTS RELATED TO 2017 SALES OF NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE

BRIEF-Opiant Pharmaceuticals Receives About $5.3 Mln Of Cash From Exercise Of Outstanding Warrants

* OPIANT PHARMACEUTICALS RECEIVES APPROXIMATELY $5.3 MILLION OF CASH FROM EXERCISE OF OUTSTANDING WARRANTS Source text for Eikon: Further company coverage:

BRIEF-Opiant Pharma Reports Financial Developments Related To Narcan Nasal Spray For Opioid Overdose

* OPIANT PHARMACEUTICALS ANNOUNCES SIGNIFICANT FINANCIAL DEVELOPMENTS RELATED TO NARCAN® NASAL SPRAY FOR OPIOID OVERDOSE

BRIEF-Opiant Pharmaceuticals, Inc. Reports Qtrly ‍net Loss Per Common Share $2.77​

* OPIANT PHARMACEUTICALS, INC. REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Opiant pharmaceuticals says ‍may offer & sell its shares through Cantor Fitzgerald

* Opiant Pharmaceuticals says ‍may offer & sell through Cantor Fitzgerald its shares having aggregate offering price of up to $25 million - SEC filing​ Source text (http://bit.ly/2gQyRPi) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Opiant Pharmaceuticals files for mixed shelf of upto $150 mln

* Opiant Pharmaceuticals Inc files for mixed shelf of upto $150 million - sec filing ‍​ Source text : http://bit.ly/2gmIQz2 Further company coverage:

BRIEF-Opiant Pharmaceuticals reports Q4 loss per share $0.17‍​

* Opiant Pharmaceuticals Inc reports fiscal fourth quarter and full year 2017 financial results and provides corporate update

BRIEF-Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

* Titan Pharmaceuticals and Opiant Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

BRIEF-Opiant Pharma, Titan Pharmac to explore new treatments for opioid abuse

* Opiant Pharmaceuticals and Titan Pharmaceuticals collaborate to explore a new approach to opioid use disorder treatment

Select another date: